Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials

Reuters02-02

<a href="https://laohu8.com/S/AORT">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials

Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608861843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608861843","market":"nz","top_or_hot":-1,"title":"Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL9bY3Sw:1","article_id":"2608861843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608861843","pubTimestamp":1770037300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry  tears between one- and two-year follow-up. The results were presented at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4082":"医疗保健设备","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC"},"translate_title":"Artivion在NEXUS TRIOMPHE和AMDS PERSEVERE试验中报告了高生存率和低发病率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":0.9},"content_text":"Artivion Reports Strong Survival and Low Morbidity in NEXUS TRIOMPHE and AMDS PERSEVERE Trials\n    \n\n        Artivion Inc. has announced the presentation of new clinical data from two trials—the NEXUS TRIOMPHE IDE trial and the AMDS PERSEVERE IDE trial—at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial, which enrolled 94 high-risk patients with chronic aortic arch disease, reported 94% survival from lesion-related death and 91% freedom from disabling stroke at one year post-treatment. Additionally, 97% of patients were free from reintervention due to endoleaks, with no cases of renal failure and one instance of paraplegia observed. Data from the AMDS PERSEVERE IDE trial indicated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between one- and two-year follow-up. The results were presented at the conference.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL75854) on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608861843","isCrawlerRequest":true}